Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.49 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PARG | Q86W56 | 1/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8916277 | 0.90 | PLA2G10 (0.47) | PLA2G10PLA2G5SCN9ASCN10AKDM4E | |
| SCHEMBL6282329 | 0.90 | PLA2G10 (0.47) | PLA2G10PLA2G5SCN9ASCN10AKDM4E | |
| SCHEMBL6283587 | 0.83 | LMNA (0.48) | PLA2G10PLA2G5SCN9ASCN10AKDM4E | |
| SCHEMBL20571667 | 0.77 | GAA (0.47) | PLA2G10PLA2G5SCN9ASCN10AKDM4E | |
| SCHEMBL27467093 | 0.76 | PLA2G10 (0.43) | PLA2G10PLA2G5SCN9ASCN10AKDM4E | |
| SCHEMBL6283002 | 0.75 | CYP2D6 (0.65) | PLA2G10PLA2G5SCN9ASCN10AKDM4E | |
| SCHEMBL3588482 | 0.75 | SCN9A (0.53) | PLA2G10PLA2G5SCN9ASCN10AKDM4E | |
| SCHEMBL907413 | 0.74 | CYP2D6 (0.51) | KDM4EALDH1A1KMT2ALMNAPER2 | |
| SCHEMBL32677269 | 0.74 | PLA2G10 (0.32) | PLA2G10PLA2G5 | |
| SCHEMBL1364804 | 0.73 | TSHR (0.54) | PLA2G10PLA2G5KDM4EALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12129236-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| CN-112979631-A | PARG inhibiting compounds | 癌症研究科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10995073-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| CN-107295799-B | PARG inhibiting compounds | 癌症研究科技有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| EP-3233845-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | PARP11, PARG, PARP16 | PLA2G10 988/4885PLA2G5 340/4885SCN9A 4502/4885 |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | PLA2G10 943/4885PLA2G5 340/4885SCN9A 4407/4885 |
| US-10995073-B2 | PARG inhibitory compounds | PARG, PARP11, PARP16 | PLA2G10 943/4885PLA2G5 340/4885SCN9A 4407/4885 |
| US-12129236-B2 | PARG inhibitory compounds | PARP11, PARG, PARP16 | PLA2G10 988/4885PLA2G5 340/4885SCN9A 4502/4885 |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | PLA2G10 943/4885PLA2G5 340/4885SCN9A 4407/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | PLA2G10 943/4885PLA2G5 340/4885SCN9A 4407/4885 |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | PLA2G10 2197/4885PLA2G5 2031/4885SCN9A 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.